Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.

BMC Neurol · 2024 · PMC11460132 · PMID 39379875

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Ozanimod was found to significantly outperform placebo in the MBMA, but the same comparison did not reach statistical significance in the NMA.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.